Literature DB >> 27521446

Multiparametric Genomic Assays for Breast Cancer: Time for the Next Generation?

Adam M Brufsky1, Nancy E Davidson2.   

Abstract

The Breast Cancer Index appears to perform better than the 21-gene recurrence score in predicting 10-year disease-free survival in postmenopausal women with hormone receptor-positive lymph node-negative early-stage breast cancer. This may have implications for clinical use of first-generation versus second-generation multiparametric genomic assays. Clin Cancer Res; 22(20); 4963-5. ©2016 AACRSee related article by Sestak et al., p. 5043. ©2016 American Association for Cancer Research.

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27521446      PMCID： PMC5154749          DOI： 10.1158/1078-0432.CCR-16-1513

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN： 1078-0432            Impact factor:   12.531


  10 in total

1.  Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer.

Authors:  Soonmyung Paik; Gong Tang; Steven Shak; Chungyeul Kim; Joffre Baker; Wanseop Kim; Maureen Cronin; Frederick L Baehner; Drew Watson; John Bryant; Joseph P Costantino; Charles E Geyer; D Lawrence Wickerham; Norman Wolmark
Journal:  J Clin Oncol       Date:  2006-05-23       Impact factor: 44.544

2.  Computer program to assist in making decisions about adjuvant therapy for women with early breast cancer.

Authors:  P M Ravdin; L A Siminoff; G J Davis; M B Mercer; J Hewlett; N Gerson; H L Parker
Journal:  J Clin Oncol       Date:  2001-02-15       Impact factor: 44.544

3.  Prospective Validation of a 21-Gene Expression Assay in Breast Cancer.

Authors:  Joseph A Sparano; Robert J Gray; Della F Makower; Kathleen I Pritchard; Kathy S Albain; Daniel F Hayes; Charles E Geyer; Elizabeth C Dees; Edith A Perez; John A Olson; JoAnne Zujewski; Tracy Lively; Sunil S Badve; Thomas J Saphner; Lynne I Wagner; Timothy J Whelan; Matthew J Ellis; Soonmyung Paik; William C Wood; Peter Ravdin; Maccon M Keane; Henry L Gomez Moreno; Pavan S Reddy; Timothy F Goggins; Ingrid A Mayer; Adam M Brufsky; Deborah L Toppmeyer; Virginia G Kaklamani; James N Atkins; Jeffrey L Berenberg; George W Sledge
Journal:  N Engl J Med       Date:  2015-09-27       Impact factor: 91.245

4.  Predicting distant recurrence in receptor-positive breast cancer patients with limited clinicopathological risk: using the PAM50 Risk of Recurrence score in 1478 postmenopausal patients of the ABCSG-8 trial treated with adjuvant endocrine therapy alone.

Authors:  M Gnant; M Filipits; R Greil; H Stoeger; M Rudas; Z Bago-Horvath; B Mlineritsch; W Kwasny; M Knauer; C Singer; R Jakesz; P Dubsky; F Fitzal; R Bartsch; G Steger; M Balic; S Ressler; J W Cowens; J Storhoff; S Ferree; C Schaper; S Liu; C Fesl; T O Nielsen
Journal:  Ann Oncol       Date:  2013-12-16       Impact factor: 32.976

5.  Cross-Stratification and Differential Risk by Breast Cancer Index and Recurrence Score in Women with Hormone Receptor-Positive Lymph Node-Negative Early-Stage Breast Cancer.

Authors:  Ivana Sestak; Yi Zhang; Brock E Schroeder; Catherine A Schnabel; Mitch Dowsett; Jack Cuzick; Dennis Sgroi
Journal:  Clin Cancer Res       Date:  2016-06-01       Impact factor: 12.531

6.  Prognostic value of a combined estrogen receptor, progesterone receptor, Ki-67, and human epidermal growth factor receptor 2 immunohistochemical score and comparison with the Genomic Health recurrence score in early breast cancer.

Authors:  Jack Cuzick; Mitch Dowsett; Silvia Pineda; Christopher Wale; Janine Salter; Emma Quinn; Lila Zabaglo; Elizabeth Mallon; Andrew R Green; Ian O Ellis; Anthony Howell; Aman U Buzdar; John F Forbes
Journal:  J Clin Oncol       Date:  2011-10-11       Impact factor: 44.544

7.  Validation and clinical utility of a 70-gene prognostic signature for women with node-negative breast cancer.

Authors:  Marc Buyse; Sherene Loi; Laura van't Veer; Giuseppe Viale; Mauro Delorenzi; Annuska M Glas; Mahasti Saghatchian d'Assignies; Jonas Bergh; Rosette Lidereau; Paul Ellis; Adrian Harris; Jan Bogaerts; Patrick Therasse; Arno Floore; Mohamed Amakrane; Fanny Piette; Emiel Rutgers; Christos Sotiriou; Fatima Cardoso; Martine J Piccart
Journal:  J Natl Cancer Inst       Date:  2006-09-06       Impact factor: 13.506

8.  Prognostic utility of HOXB13:IL17BR and molecular grade index in early-stage breast cancer patients from the Stockholm trial.

Authors:  P-L Jerevall; X-J Ma; H Li; R Salunga; N C Kesty; M G Erlander; D C Sgroi; B Holmlund; L Skoog; T Fornander; B Nordenskjöld; O Stål
Journal:  Br J Cancer       Date:  2011-05-10       Impact factor: 7.640

9.  Prediction of late distant recurrence in patients with oestrogen-receptor-positive breast cancer: a prospective comparison of the breast-cancer index (BCI) assay, 21-gene recurrence score, and IHC4 in the TransATAC study population.

Authors:  Dennis C Sgroi; Ivana Sestak; Jack Cuzick; Yi Zhang; Catherine A Schnabel; Brock Schroeder; Mark G Erlander; Anita Dunbier; Kally Sidhu; Elena Lopez-Knowles; Paul E Goss; Mitch Dowsett
Journal:  Lancet Oncol       Date:  2013-09-12       Impact factor: 41.316

10.  Prediction of the Oncotype DX recurrence score: use of pathology-generated equations derived by linear regression analysis.

Authors:  Molly E Klein; David J Dabbs; Yongli Shuai; Adam M Brufsky; Rachel Jankowitz; Shannon L Puhalla; Rohit Bhargava
Journal:  Mod Pathol       Date:  2013-03-15       Impact factor: 7.842
  10 in total
  2 in total

1.  Stanniocalcin Expression as a Predictor of Late Breast Cancer Recurrence.

Authors:  Kristen D Brantley; Anders Kjærsgaard; Deirdre Cronin-Fenton; Rami Yacoub; Anja S Nielsen; Kristina L Lauridsen; Stephen Hamilton-Dutoit; Timothy L Lash
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2018-03-28       Impact factor: 4.254

Review 2.  Immune Infiltrates in Breast Cancer: Recent Updates and Clinical Implications.

Authors:  Maria Vittoria Dieci; Federica Miglietta; Valentina Guarneri
Journal:  Cells       Date:  2021-01-23       Impact factor: 6.600
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.